A POOLED SAFETY ANALYSIS OF OVER 6000 PATIENTS FROM DOUBLE-BLIND AND OPEN-LABEL EXTENSION STUDIES WITH EVOLOCUMAB

Evolocumab, a fully human monoclonal antibody to PCSK9, markedly reduces LDL-C and is well tolerated in diverse patient populations. We report a pooled safety analysis for patients participating in evolocumab phase 2 or 3 randomized and placebo/comparator-controlled trials and in open-label